Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, ...

Here's a look at the best and worst states in each of the four data categories: mental health provider ratio, suicide rate ...

Researchers found that psilocybin therapy provides long-term relief from depressive symptoms similar to escitalopram while ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

A direct comparison between the experimental psychedelic drug psilocybin and a standard SSRI antidepressant shows similar improvement of depressive symptoms, but that psilocybin offers additional ...

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price ...

Dysthymia, now more commonly referred to as Persistent Depressive Disorder (PDD), is a chronic form of depression ...